1.17% 0.0049

Evoke Pharma Inc (EVOK)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Evoke Pharma Inc Stock (EVOK) Company Profile

Evoke Pharma Inc

Healthcare (1173)

858-345-1494

420 STEVENS AVENUE, SOLANA BEACH, CA

Prossima data di guadagno

Ultimi documenti SEC

EVOK's Discussions on Twitter

Confronta EVOK con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
EVOK Evoke Pharma Inc	5.14	3.97M	8.62M	-6.15M	-5.32M	-11.03
ZTS Zoetis Inc	151.35	70.25B	9.29B	2.52B	2.28B	5.57
TAK Takeda Pharmaceutical Co Adr	14.66	47.44B	30.08B	710.16M	4.45B	0.2182
HLN Haleon Plc Adr	9.70	45.15B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	15.88	19.07B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	298.86	13.28B	2.99B	1.21B	1.13B	25.06

Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2020-06-22	Aggiornamento	H.C. Wainwright	Neutral → Buy
2019-03-05	Downgrade	H.C. Wainwright	Buy → Neutral
2018-03-08	Reiterato	B. Riley FBR, Inc.	Buy
2017-10-19	Ripresa	FBR & Co.	Buy
2017-03-16	Reiterato	Rodman & Renshaw	Buy
2017-01-30	Aggiornamento	Laidlaw	Neutral → Buy
2017-01-05	Aggiornamento	Rodman & Renshaw	Neutral → Buy
2016-12-23	Reiterato	Rodman & Renshaw	Neutral
2016-07-19	Reiterato	FBR Capital	Outperform
2016-07-19	Downgrade	Noble Financial	Buy → Hold
2016-07-18	Downgrade	Rodman & Renshaw	Buy → Neutral
2016-03-16	Iniziato	Northland Capital	Outperform
2016-03-14	Reiterato	Ascendiant Capital Markets	Buy
2016-02-17	Ripresa	FBR Capital	Outperform
2014-12-03	Reiterato	MLV & Co	Buy
2014-11-07	Iniziato	MLV & Co	Buy
2014-04-22	Iniziato	Laidlaw	Buy
2013-11-19	Iniziato	Aegis Capital	Buy

Mostra tutto

Evoke Pharma Inc Borsa (EVOK) Ultime notizie

Evoke Pharma Inc Azioni (EVOK) Dati Finanziari

Evoke Pharma Inc (EVOK)

Evoke Pharma Inc Stock (EVOK) Company Profile

Confronta EVOK con altri titoli

Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades

Evoke Pharma Inc Borsa (EVOK) Ultime notizie

Why Evoke Pharma Inc. stock attracts strong analyst attentionStrong Buy Recommendations - Newser

What makes Evoke Pharma Inc. stock price move sharplyVerified Chart Patterns - Newser

How Evoke Pharma Inc. stock performs during market volatilityFree Real-Time Stock Data - Newser

Small Cap Stocks Worth Watching – July 9th - Defense World

Promising Pharmaceutical Stocks To Watch Now – July 9th - Defense World

Evoke Pharma Shares Jump 50% Following Patent Approval for GIMOTI - MSN

Evoke Pharma skyrockets on patent allowance for diabetes nasal spray drug - Mugglehead Magazine

Evoke Pharma Stock Skyrockets On Patent For Nasal Spray That Eases Stomach Delays; Retail Bulls Pile In - Asianet Newsable

Evoke Pharma receives patent allowance for gastroparesis nasal spray By Investing.com - Investing.com South Africa

Evoke Pharma (EVOK) Soars 162.78% on Patent Extension - AInvest

Evoke Pharma shares surge 24.57% intraday after receiving Notice of Allowance for U.S. patent application for GIMOTI®. - AInvest

Evoke Pharma (EVOK) Shares Skyrocket On New Patent: What's Going On? - Benzinga

Dow Jumps 200 Points; US Wholesale Inventories Fall 0.3% In May - Benzinga

Evoke Pharma Shares Soar After Patent Allowance for Gastroparesis Treatment - MarketScreener

Evoke Pharma (EVOK) Stock Soars Following Positive Patent News - Stocks Telegraph

Evoke Pharma: Is the Bounce Back Real? - StocksToTrade

EVOK Stock: Boom or Bust? - timothysykes.com

Evoke Pharma (EVOK) Secures New Patent Approval for GIMOTI | EVO - GuruFocus

Evoke Pharma stock soars after receiving patent allowance for GIMOTI By Investing.com - Investing.com Nigeria

Evoke Pharma stock soars after receiving patent allowance for GIMOTI - Investing.com

Evoke Pharma (EVOK) Secures Key Patent for Gastroparesis Treatment | EVOK Stock News - GuruFocus

Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036 | EVOK Stock News - GuruFocus

Evoke Pharma, Inc. Receives Patent Allowance for GIMOTI® in Treatment of Gastroparesis Symptoms - Quiver Quantitative

Evoke Pharma Receives Notice of Allowance for U.S. Patent - GlobeNewswire

Major Patent Win: GIMOTI Locks Down 6 More Years of Exclusivity for Revolutionary Gastroparesis Spray - Stock Titan

Evoke Pharma Secures Patent for GIMOTI Treatment - TipRanks

GILT lands >$22M Tier-One satellite orders, boosts multi-orbit momentum | EVOK SEC FilingForm 8-K - Stock Titan

Evoke Pharma (NASDAQ:EVOK) versus Teva Pharmaceutical Industries (NYSE:TEVA) Head to Head Review - Defense World

Evoke Pharma (NASDAQ:EVOK) Stock Price Crosses Below Two Hundred Day Moving Average – What’s Next? - Defense World

Spine Injury Solutions (OTCMKTS:SPIN) Stock Price Crosses Below 200-Day Moving Average – Should You Sell? - Defense World

Breakeven On The Horizon For Evoke Pharma, Inc. (NASDAQ:EVOK) - Yahoo Finance

Gastroparesis Treatment Market Booming Worldwide with - openPR.com

Diabetic Gastroparesis Pipeline 2025: Key Developments, - openPR.com

Geriatric Medicines Market Expands Globally with Aging - openPR.com

Diabetic Gastroparesis Treatment Market Size, Trends & - openPR.com

Global Geriatric Medicines Market Generated Opportunities, - openPR.com

Diabetic Gastroparesis Treatment Market in 2025-2032 Detailed - openPR.com

Evoke Pharma Holds Annual Meeting via Webcast - TipRanks

Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com - Defense World

Barclays PLC Makes New $122,000 Investment in Innovator Equity Defined Protection ETF – 2 Yr to July 2026 (BATS:AJUL) - Defense World

Raymond James Financial Inc. Takes Position in Metalla Royalty & Streaming Ltd. (NYSEMKT:MTA) - Defense World

Evoke Pharma Reports Strong Q1 2025 Sales Growth - TipRanks

Evoke Pharma Reports First Quarter 2025 Financial Results and Pr - GuruFocus

Evoke Pharma, Inc. Q1 Loss Decreases, But Misses Estimates - Nasdaq

Evoke Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView

Evoke Pharma Q1 Operating Expenses USD 4.4 Million - marketscreener.com

Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times

Evoke Pharma Reports 77% Increase in Q1 2025 Net Product Sales, Driven by GIMOTI Adoption and Provider Engagement - Nasdaq

Evoke Pharma (EVOK) to Release Earnings on Tuesday - Defense World

Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com - Defense World

EVOKEvoke Pharma Inc Latest Stock News & Market Updates - Stock Titan

Evoke Pharma Inc Azioni (EVOK) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a EVOK